Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MANGOCEUTICALS, INC.

Get SEC filing alerts via email and in your feed for MANGOCEUTICALS, INC.

MGRX

MANGOCEUTICALS, INC.

About MANGOCEUTICALS, INC.

Mangoceuticals, Inc. develops and markets telehealth-based men's wellness products and pharmaceutical therapies, including treatments for erectile dysfunction, hair loss, hormone balance, and weight management. The company connects consumers with licensed healthcare providers via its platform, offering compounded and FDA-approved medications. It operates through a network of telemedicine providers, a related pharmacy, and a proprietary customer portal, focusing on personalized, subscription-based health solutions.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from MANGOCEUTICALS, INC.

1
1
MANGOCEUTICALS, INC. Mangoceuticals Reports 38% Revenue Decline in Q1 2026, Net Loss Improves

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
MANGOCEUTICALS, INC. Mangoceuticals Reports $456,021 Revenue Decline and $20.6 Million Net Loss for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
MANGOCEUTICALS, INC. Mangoceuticals Reports Significant Revenue Decline and Increased Net Loss in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
MANGOCEUTICALS, INC. Mangoceuticals Reports Revenue Increase in Q2 2025 but Significant Net Loss

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
MANGOCEUTICALS, INC. Mangoceuticals Reports 49% Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MANGOCEUTICALS, INC. Mangoceuticals Reports $615,873 Revenue and $8.7M Net Loss for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MANGOCEUTICALS, INC. Mangoceuticals Reports 45.6% Revenue Decline in Q3, Net Loss Increases Amid Migration Issues and Patent Acquisition

Via official filing (AI summary) | over 1 year ago | 0 comments